2-methylimidazolium acetate | 7538-99-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-methylimidazolium acetate
• 英文别名: Acetic acid--2-methyl-1H-imidazole (1/1)；acetic acid;2-methyl-1H-imidazole
• CAS: 7538-99-0
• 化学式: C₂H₄O₂*C₄H₆N₂
• 分子量: 142.158
• InChiKey: PYBVIVSKAOAMAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.81
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  66
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-甲基咪唑 、 溶剂黄146 反应 1.16h， 生成 2-methylimidazolium acetate
  参考文献：
  名称：

  咪唑基离子液体的结构和光学性质受半导体金属氧化物薄膜的影响

  摘要：

  本文报道了通过微波辐射法通过简单的质子转移反应制备两种质子离子液体（PIL）乳酸2-甲基咪唑鎓盐和乙酸2-甲基咪唑鎓盐。这项工作进一步改善了诸如CuO（p型），ZnO（n型）[两种过渡金属氧化物]和SnO 2（n型非过渡金属氧化物）之类的半导体金属氧化物对合成PIL的影响。这些金属氧化物通过溶胶-凝胶法制备，并通过旋涂法制备薄膜而掺杂在合成的IL上。本研究的重点是了解在PIL上掺入p型和n型金属氧化物的带隙如何变化。通过FT-IR，UV-Visible，光致发光和XRD光谱研究了它们的结构，光学性质和形态。

  DOI：

  10.1016/j.molliq.2017.06.132

文献信息

• ISOCYANATE TRIMERISATION CATALYST SYSTEM, A PRECURSOR FORMULATION, A PROCESS FOR TRIMERISING ISOCYANATES, RIGID POLYISOCYANURATE/POLYURETHANE FOAMS MADE THEREFROM, AND A PROCESS FOR MAKING SUCH FOAMS
  申请人：Athey Phillip

  公开号：US20110201709A1

  公开（公告）日：2011-08-18

  The instant invention provides an isocyanate trimerisation catalyst system, a precursor formulation, a process for trimerising isocyanates, rigid foams made therefrom, and a process for making such foams. The trimerisation catalyst system comprises: (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The precursor formulation comprises: (1) at least 25 percent by weight of polyol, based on the weight of the precursor formulation; (2) less than 15 percent by weight of a trimerisation catalyst system, based on the weight of the precursor formulation, comprising; (a) an imidazolium or imidazolinium cation; and (c) an isocyanate-trimer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (3) optionally one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof. The process for trimerisation of isocyanates comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture of any thereof; (2) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-trimer inducing anion; (c) wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; (3) trimerising said one or more monomers in the presence of said trimerisation catalyst; (4) thereby forming an isocyanurate trimer. The process for making the PIR foam comprises the steps of: (1) providing one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof; (2) providing polyol; (3) providing a trimerisation catalyst system comprising; (a) an imidazolium or imidazolinium cation; and (b) an isocyanate-timer inducing anion; wherein said trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C.; and (4) optionally providing one or more surfactants, one or more flame retardants, water, one or more antioxidants, one or more auxiliary blowing agents, one or more urethane catalysts, one or more auxiliary trimerisation catalysts, or combinations thereof; (5) contacting said one or more monomers, and said polyol, and optionally said one or more surfactants, and optionally said one or more flame retardants, and optionally said water, and optionally said one or more antioxidants, and optionally said one or more auxiliary blowing agents in the presence of said trimerisation catalyst system and optionally said one or more urethane catalysts, and optionally said one or more auxiliary trimerisation catalysts; (6) thereby forming said polyisocyanurate/polyurethane rigid foam. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional urethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the trimerisation catalyst system has a trimerisation activation temperature in the range of equal to or less than 73° C. The PIR foam comprises the reaction product of one or more monomers selected from the group consisting of an isocyanate, a diisocyanate, a triisocyanatetriisocyanate, oligomeric isocyanate, a salt of any thereof, and a mixture any thereof with polyol in the presence of a trimerisation catalyst system comprising an imidazolium or imidazolinium cation, and an isocyanate-trimer inducing anion, and optionally one or more surfactants, optionally one or more flame retardants, optionally water, optionally one or more antioxidants, optionally one or more auxiliary blowing agents, optionally one or more additional polyurethane catalysts, and optionally one or more auxiliary trimerisation catalysts, or optionally combinations thereof, wherein the PIR foam has a polyisocyanurate trimer ratio (Abs 1410 /Abs 1595 ) of at least 5 at a depth of 12 mm from the rising surface of the rigid foam, measured via ATR-FTIR spectroscopy.

  该发明提供了一种异氰酸酯三聚催化剂系统、前体配方、异氰酸酯三聚化过程、由此制成的硬质泡沫以及制备此类泡沫的方法。该三聚化催化剂系统包括：(a)咪唑或咪唑啉阳离子；以及(b)异氰酸酯三聚诱导阴离子；其中所述的三聚化催化剂系统具有等于或小于73℃的三聚化活化温度。前体配方包括：(1)聚醚醇，其重量占前体配方重量的至少25%；(2)三聚化催化剂系统，其重量占前体配方重量的15%以下，包括：(a)咪唑或咪唑啉阳离子；(b)异氰酸酯三聚诱导阴离子；其中所述的三聚化催化剂系统具有等于或小于73℃的三聚化活化温度；以及(3)可选的一个或多个表面活性剂、一个或多个阻燃剂、水、一个或多个抗氧化剂、一个或多个辅助发泡剂、一个或多个脲催化剂、一个或多个辅助三聚化催化剂或其组合。异氰酸酯三聚化过程包括以下步骤：(1)提供一种或多种单体，所述单体选自群组中的异氰酸酯、二异氰酸酯、三异氰酸酯三异氰酸酯、寡聚异氰酸酯、任何其中的盐以及任何其中的混合物；(2)提供三聚化催化剂系统，包括：(a)咪唑或咪唑啉阳离子；以及(b)异氰酸酯三聚诱导阴离子；其中所述的三聚化催化剂系统具有等于或小于73℃的三聚化活化温度；(3)在所述三聚化催化剂的存在下，三聚化所述的一种或多种单体；(4)从而形成异氰酸酯三聚体。制备PIR泡沫的方法包括以下步骤：(1)提供一种或多种单体，所述单体选自群组中的异氰酸酯、二异氰酸酯、三异氰酸酯三异氰酸酯、寡聚异氰酸酯、任何其中的盐以及任何其中的混合物；(2)提供聚醚醇；(3)提供三聚化催化剂系统，包括：(a)咪唑或咪唑啉阳离子；以及(b)异氰酸酯三聚诱导阴离子；其中所述的三聚化催化剂系统具有等于或小于73℃的三聚化活化温度；以及(4)可选地提供一个或多个表面活性剂、一个或多个阻燃剂、水、一个或多个抗氧化剂、一个或多个辅助发泡剂、一个或多个脲催化剂、一个或多个辅助三聚化催化剂或其组合；(5)在所述三聚化催化剂系统和可选的一个或多个脲催化剂以及可选的一个或多个辅助三聚化催化剂的存在下，将所述的一种或多种单体、所述的聚醚醇、可选的一个或多个表面活性剂、可选的一个或多个阻燃剂、可选的水、可选的一个或多个抗氧化剂以及可选的一个或多个辅助发泡剂接触；(6)从而形成所述的聚异氰酸酯/聚氨酯硬质泡沫。PIR泡沫是由异氰酸酯、二异氰酸酯、三异氰酸酯三异氰酸酯、寡聚异氰酸酯、任何其中的盐以及任何其中的混合物和聚醚醇在咪唑或咪唑啉阳离子和异氰酸酯三聚诱导阴离子以及可选的一个或多个表面活性剂、可选的一个或多个阻燃剂、可选的水、可选的一个或多个抗氧化剂、可选的一个或多个辅助发泡剂、可选的一个或多个额外脲催化剂以及可选的一个或多个辅助三聚化催化剂或其组合的存在下的反应产物，其中所述的三聚化催化剂系统具有等于或小于73℃的三聚化活化温度。PIR泡沫在距硬质泡沫上升表面12mm处通过ATR-FTIR光谱测量具有聚异氰酸酯三聚体比值(Abs1410/Abs1595)至少为5。
• BIOCONDITION EVALUATING DEVICE, BIOCONDITION EVALUATING METHOD, BIOCONDITION EVALUATING SYSTEM, BIOCONDITION EVALUATING PROGRAM, EVALUATION FUNCTION GENERATING DEVICE, EVALUATION FUNCTION GENERATING METHOD, EVALUATION FUNCTION GENERATING PROGRAM, AND RECORDING MEDIUM
  申请人：Ajinomoto Co., Inc.

  公开号：EP1862797A1

  公开（公告）日：2007-12-05

  Provided are a biological state-evaluating apparatus allowing accurate evaluation of the biological state of an evaluation subject by using a verified evaluation function, a biological state-evaluating method, a biological state-evaluating system, a biological state-evaluating program, a recording medium, and the like. The biological state-evaluating system according to the present invention includes a biological state-evaluating apparatus 100 that evaluates biological state and information communication terminal apparatuses 200 that provide the metabolite concentration data to be evaluated, communicatively connected thereto via a network 300. The biological state-evaluating apparatus 100 generates an evaluation function having the metabolite concentration as the variable, based on previously-obtained biological state information including metabolite concentration data concerning metabolite concentration and biological state indicator data concerning the indicator showing the biological state, and evaluates the biological state to be evaluated, based on the generated evaluation function and the previously acquired metabolite concentration data to be evaluated.

  本发明提供了一种生物状态评估装置，可通过使用验证评估功能准确评估评估对象的生物状态；还提供了一种生物状态评估方法、一种生物状态评估系统、一种生物状态评估程序、一种记录介质等。根据本发明，生物状态评估系统包括评估生物状态的生物状态评估装置 100 和提供待评估代谢物浓度数据的信息通信终端设备 200，它们通过网络 300 通信连接。生物状态评估装置 100 根据先前获得的生物状态信息（包括关于代谢物浓度的代谢物浓度数据和关于显示生物状态的指标的生物状态指标数据）生成以代谢物浓度为变量的评估函数，并根据生成的评估函数和先前获得的待评估代谢物浓度数据评估待评估生物状态。
• Polyisocyanate polyaddition polyol manufacturing process using stabilizers
  申请人：DOW GLOBAL TECHNOLOGIES LLC

  公开号：US10017599B2

  公开（公告）日：2018-07-10

  PIPA polyols are made by reacting a low equivalent weight polyol with a polyisocyanate in the presence of a stabilizer. Low amounts, if any, of water are present. Useful stabilizers include functionalized linear or branched polyethers having at least one polyether segment having a molecular weight of 200 to 8000, wherein the functionalized polyether is terminated at one end with one or more isocyanate groups or with one or more isocyanate-reactive groups linked to the polyether through one or more urea and/or urethane groups, and further wherein all or a portion of such functionalized polyether contains one or more biuret, isocyanurate, urea or allophonate groups.

  PIPA 多元醇是通过低当量多元醇与多异氰酸酯在稳定剂存在的情况下发生反应而制成的。水的含量很低（如果有的话）。有用的稳定剂包括具有至少一个分子量为 200-8000 的聚醚段的官能化线性或支化聚醚，其中官能化聚醚的一端以一个或多个异氰酸酯基团或通过一个或多个脲和/或氨基甲酸酯基团与聚醚相连的一个或多个异氰酸酯反应基团为端基，此外，这种官能化聚醚的全部或部分含有一个或多个双缩氨基脲酸酯、异氰尿酸酯、脲或异膦酸酯基团。
• Methods for the treatment of mast cell related disorders with mast cell stabilizers
  申请人：Respivant Sciences GmbH

  公开号：US10238625B2

  公开（公告）日：2019-03-26

  Methods for the treatment of systemic mast cell related disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

  提供了可使用肥大细胞稳定剂治疗全身性肥大细胞相关疾病（包括肥大细胞相关疾病）的方法。
• Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
  申请人：Respivant Sciences GmbH

  公开号：US10265296B2

  公开（公告）日：2019-04-23

  Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided.

  本研究提供了用肥大细胞稳定剂治疗全身性疾病（包括肥大细胞相关疾病）的方法。